Forte Biosciences (FBRX) to be acquired by argenx in $77-per-share cash deal
Forte Biosciences (FBRX) reported a $45.5 million net loss for the six months ended June 30, 2026, up from $26.9 million a year earlier, citing higher FB102 clinical and manufacturing spending. Cash and investments totaled $198.5 million after a $172.5 million April 2026 equity offering. Forte agreed to be acquired by argenx via a $77-per-share cash tender offer and merger.
How this was made
The 30-second read
Why it matters
The acquisition terms (cash tender at $77, followed by merger) reframe Forte’s standalone clinical and burn-rate story into a binary deal-completion trade.
Market read
This is a direct M&A catalyst with a stated per-share cash price and deal mechanics that can drive immediate repricing and deal-spread trading.
What to watch
The article notes a $65M termination fee and customary conditions; traders should monitor which specific conditions are most likely to delay or derail closing.
Background
Forte is pre-revenue with an accumulated deficit and is advancing FB102 through early-stage autoimmune indications while pursuing financing.
Ticker impact
Forte agreed to be acquired by argenx via a cash tender offer at $77.00 per share, with a potential $65M termination fee.
Expect spread compression if deal conditions progress; downside risk if regulatory or other conditions fail.
The article discloses the bid price, tender commencement, and termination fee, which are direct drivers of deal-spread behavior.
Market effects
Signals continued consolidation in autoimmune biotech and may lift sentiment for pre-revenue clinical-stage peers, though impact is indirect.
Primarily US biotech takeover dynamics; limited direct regional spillover beyond deal arbitrage flows.
Argentx is a global biotech acquirer, but the disclosed catalyst is company-specific rather than a broad cross-border policy shift.
Counterpoint
Even with a $77 offer, deal completion risk can keep the stock below offer price if conditions or antitrust review become contentious.
Key entities
- companyForte Biosciences
Subject of the acquisition, reporting higher H1 2026 net loss and advancing FB102.
- acquirerargenx BV
Agreed to acquire Forte via a cash tender offer at $77 per share.
- assetFB102
Lead autoimmune candidate with positive Phase 1b data and ongoing Phase 1b/Phase 2 studies.
